ZA200401390B - Sustained release of microcrystalline peptide suspensions. - Google Patents
Sustained release of microcrystalline peptide suspensions. Download PDFInfo
- Publication number
- ZA200401390B ZA200401390B ZA200401390A ZA200401390A ZA200401390B ZA 200401390 B ZA200401390 B ZA 200401390B ZA 200401390 A ZA200401390 A ZA 200401390A ZA 200401390 A ZA200401390 A ZA 200401390A ZA 200401390 B ZA200401390 B ZA 200401390B
- Authority
- ZA
- South Africa
- Prior art keywords
- suspension
- peptide
- gnrh
- gnrh antagonist
- aqueous
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 39
- 238000013268 sustained release Methods 0.000 title claims description 8
- 239000012730 sustained-release form Substances 0.000 title claims description 8
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 18
- 230000002209 hydrophobic effect Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 239000007900 aqueous suspension Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000007951 isotonicity adjuster Substances 0.000 claims description 5
- 239000013081 microcrystal Substances 0.000 claims description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 108010023617 abarelix Proteins 0.000 claims description 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 3
- 229960002184 abarelix Drugs 0.000 claims description 3
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 claims description 3
- 229940127233 azaline B Drugs 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 108700008462 cetrorelix Proteins 0.000 claims description 3
- 229960003230 cetrorelix Drugs 0.000 claims description 3
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 3
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 claims description 3
- 108700032141 ganirelix Proteins 0.000 claims description 3
- 229960003794 ganirelix Drugs 0.000 claims description 3
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 3
- 108010083551 iturelix Proteins 0.000 claims description 3
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 108010070670 antarelix Proteins 0.000 description 16
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 15
- 229950011372 teverelix Drugs 0.000 description 14
- 239000000499 gel Substances 0.000 description 12
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- 238000009472 formulation Methods 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000257465 Echinoidea Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31761601P | 2001-09-06 | 2001-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200401390B true ZA200401390B (en) | 2004-08-27 |
Family
ID=23234486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200401390A ZA200401390B (en) | 2001-09-06 | 2004-02-20 | Sustained release of microcrystalline peptide suspensions. |
Country Status (27)
Country | Link |
---|---|
US (5) | US7098305B2 (zh) |
EP (2) | EP2198888B1 (zh) |
JP (3) | JP2005504787A (zh) |
KR (2) | KR100818904B1 (zh) |
CN (1) | CN100386116C (zh) |
AR (1) | AR042592A1 (zh) |
AT (1) | ATE463258T1 (zh) |
AU (1) | AU2002337025B2 (zh) |
BR (1) | BR0212333A (zh) |
CA (1) | CA2459309C (zh) |
CY (1) | CY1118642T1 (zh) |
DE (1) | DE60235896D1 (zh) |
DK (1) | DK2198888T3 (zh) |
ES (2) | ES2362505T3 (zh) |
HK (1) | HK1062148A1 (zh) |
HU (1) | HUP0402099A2 (zh) |
IL (1) | IL160443A0 (zh) |
MX (1) | MXPA04002185A (zh) |
NO (1) | NO20040938L (zh) |
NZ (1) | NZ531734A (zh) |
PL (1) | PL368056A1 (zh) |
PT (1) | PT2198888T (zh) |
RU (1) | RU2311195C2 (zh) |
TW (1) | TWI249409B (zh) |
UA (1) | UA79435C2 (zh) |
WO (1) | WO2003022243A2 (zh) |
ZA (1) | ZA200401390B (zh) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
AU2003263964C1 (en) | 2002-07-31 | 2010-08-19 | Seagen Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
AR044852A1 (es) * | 2003-06-24 | 2005-10-05 | Novartis Ag | Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina |
GB0320806D0 (en) | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
GB0511269D0 (en) * | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
EP1984009B1 (en) * | 2006-01-18 | 2012-10-24 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
US7704977B2 (en) * | 2006-04-07 | 2010-04-27 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
WO2008071984A1 (en) * | 2006-12-13 | 2008-06-19 | Ardana Bioscience Limited | Administration of the gonadotropin-releasing hormone antagonist teverelix |
WO2009012256A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
DK2474557T3 (da) | 2007-07-16 | 2014-11-10 | Genentech Inc | Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse |
DK2657253T3 (en) | 2008-01-31 | 2017-10-09 | Genentech Inc | Anti-CD79b antibodies and immune conjugates and methods of use |
JP2011519928A (ja) * | 2008-05-07 | 2011-07-14 | メリオン・リサーチ・Iii・リミテッド | ペプチドの組成物及びその調製方法 |
CA2751854A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
EP2424503B1 (en) * | 2009-05-01 | 2017-07-05 | Ferring BV | Composition for the treatment of prostate cancer |
WO2011085957A2 (en) | 2010-01-13 | 2011-07-21 | Ipsen Pharma S.A.S. | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
US9089484B2 (en) * | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
WO2012006566A2 (en) | 2010-07-09 | 2012-01-12 | Amylin Pharmaceuticals, Inc. | Microcrystalline y receptor agonists |
AU2012204213A1 (en) | 2011-01-07 | 2013-06-13 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
EP2823808A1 (en) | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
EP2832361A1 (en) * | 2013-07-29 | 2015-02-04 | Ipsen Pharma S.A.S. | Aqueous sustained release compositions of LHRH analogs |
CN104844694A (zh) * | 2014-02-17 | 2015-08-19 | 深圳翰宇药业股份有限公司 | 一种醋酸加尼瑞克的制备方法 |
ES2960619T3 (es) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
PT3262071T (pt) | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
EP3250191B1 (en) | 2015-01-29 | 2024-01-17 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
NZ739830A (en) | 2015-07-12 | 2021-12-24 | Hangzhou Dac Biotech Co Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US20210308277A1 (en) | 2016-11-14 | 2021-10-07 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers |
US20200000872A1 (en) | 2017-01-30 | 2020-01-02 | Antev Limited | A composition comprising at least one gnrh antagonist |
US20200129583A1 (en) | 2017-06-30 | 2020-04-30 | Antev Limited | Composition for treating acute urinary retention |
EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
WO2019228307A1 (en) * | 2018-05-28 | 2019-12-05 | Jiangyin Usun Pharmaceutical Co., Ltd. | New pharmaceutical use |
EP3590524B1 (en) * | 2018-07-05 | 2020-11-04 | Antev Limited | A method of reconstituting a teverelix-tfa composition |
EP3590525A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | Teverelix-tfa composition |
EP3590526A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | A lyophilization process and a teverelix-tfa lyophilizate obtained thereby |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2668866A (en) * | 1951-08-14 | 1954-02-09 | Shell Dev | Isomerization of paraffin wax |
GB1245187A (en) | 1969-02-14 | 1971-09-08 | Continental Can Co | Hot melt adhesive composition |
JPS5242506A (en) | 1975-10-02 | 1977-04-02 | Toa Nenryo Kogyo Kk | Hydrotreating process of petroleum wax |
JPS5335705A (en) * | 1976-09-14 | 1978-04-03 | Toa Nenryo Kogyo Kk | Hydrogenation and purification of petroleum wax |
US4186078A (en) * | 1977-09-12 | 1980-01-29 | Toa Nenryo Kogyo Kabushiki Kaisha | Catalyst and process for hydrofining petroleum wax |
US4239546A (en) * | 1978-07-21 | 1980-12-16 | Petrolite Corporation | Hydrocarbon polymers to improve the hardness of waxes |
US4256737A (en) | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
US4266737A (en) * | 1979-11-05 | 1981-05-12 | Arrow Converting Equipment, Inc. | Air differential mandrel and method of differentially winding and rewinding tapes |
US4415649A (en) * | 1981-02-25 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Flexographic printing plates containing blended adhesives |
US4839422A (en) * | 1987-12-23 | 1989-06-13 | Exxon Chemical Patents Inc. | Ternary adhesive compositions |
US5110904A (en) * | 1989-08-07 | 1992-05-05 | Abbott Laboratories | Lhrh analogs |
EP0328090A3 (en) | 1988-02-10 | 1990-08-16 | Abbott Laboratories | Lhrh analogs |
JP2672677B2 (ja) | 1989-02-09 | 1997-11-05 | タツプ・フアーマシユーテイカルズ・インコーポレイテツド | Lhrh同族体 |
DE593491T1 (de) * | 1991-04-25 | 1994-11-17 | Romano S.-Cergue Deghenghi | LHRH-Antagonisten. |
EP0625069B1 (de) * | 1992-10-26 | 1998-12-30 | Schwarz Pharma Ag | Verfahren zur herstellung von mikrokapseln |
JPH08504209A (ja) | 1992-12-04 | 1996-05-07 | アボツト・ラボラトリーズ | 6位修飾デカペプチドlhrh拮抗薬 |
CA2136079A1 (en) | 1992-12-18 | 1994-07-07 | Fortuna Haviv | Lhrh antagonists having modified aminoacyl residues at positions 5 and 6 |
CA2178592C (en) | 1993-12-09 | 2009-07-28 | Jurgen Engel | Long-acting injection suspensions and a process for their preparation |
DE4342092B4 (de) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
JP3101695B2 (ja) | 1996-07-24 | 2000-10-23 | 日本航空電子工業株式会社 | 軟x線光学素子用多層膜 |
US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
DE19813849A1 (de) * | 1998-03-27 | 1999-09-30 | Degussa | Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden |
CO5160256A1 (es) | 1999-02-08 | 2002-05-30 | Zentaris Ag | Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion |
DE10040700A1 (de) * | 2000-08-17 | 2002-02-28 | Asta Medica Ag | Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung |
US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
JP4505750B2 (ja) | 2006-01-27 | 2010-07-21 | 東海ゴム工業株式会社 | 制振装置 |
-
2002
- 2002-02-19 US US10/080,130 patent/US7098305B2/en not_active Expired - Lifetime
- 2002-08-27 HU HU0402099A patent/HUP0402099A2/hu unknown
- 2002-08-27 MX MXPA04002185A patent/MXPA04002185A/es not_active Application Discontinuation
- 2002-08-27 IL IL16044302A patent/IL160443A0/xx unknown
- 2002-08-27 UA UA2004031905A patent/UA79435C2/uk unknown
- 2002-08-27 EP EP10003046.9A patent/EP2198888B1/en not_active Expired - Lifetime
- 2002-08-27 KR KR1020047003371A patent/KR100818904B1/ko active IP Right Grant
- 2002-08-27 RU RU2004110615/15A patent/RU2311195C2/ru not_active IP Right Cessation
- 2002-08-27 PT PT100030469T patent/PT2198888T/pt unknown
- 2002-08-27 JP JP2003526373A patent/JP2005504787A/ja active Pending
- 2002-08-27 DE DE60235896T patent/DE60235896D1/de not_active Expired - Lifetime
- 2002-08-27 CA CA2459309A patent/CA2459309C/en not_active Expired - Lifetime
- 2002-08-27 WO PCT/EP2002/009537 patent/WO2003022243A2/en active Application Filing
- 2002-08-27 AT AT02772214T patent/ATE463258T1/de active
- 2002-08-27 AU AU2002337025A patent/AU2002337025B2/en not_active Ceased
- 2002-08-27 DK DK10003046.9T patent/DK2198888T3/en active
- 2002-08-27 ES ES02772214T patent/ES2362505T3/es not_active Expired - Lifetime
- 2002-08-27 NZ NZ531734A patent/NZ531734A/en not_active IP Right Cessation
- 2002-08-27 CN CNB028173775A patent/CN100386116C/zh not_active Expired - Lifetime
- 2002-08-27 BR BR0212333-9A patent/BR0212333A/pt not_active IP Right Cessation
- 2002-08-27 EP EP02772214A patent/EP1423150B1/en not_active Expired - Lifetime
- 2002-08-27 PL PL02368056A patent/PL368056A1/xx unknown
- 2002-08-27 ES ES10003046.9T patent/ES2618777T3/es not_active Expired - Lifetime
- 2002-08-27 KR KR1020077021972A patent/KR20070107161A/ko not_active Application Discontinuation
- 2002-08-29 TW TW091119713A patent/TWI249409B/zh not_active IP Right Cessation
- 2002-09-05 AR ARP020103358A patent/AR042592A1/es unknown
-
2004
- 2004-02-20 ZA ZA200401390A patent/ZA200401390B/en unknown
- 2004-03-04 NO NO20040938A patent/NO20040938L/no not_active Application Discontinuation
- 2004-07-15 HK HK04105185.0A patent/HK1062148A1/xx not_active IP Right Cessation
-
2006
- 2006-06-12 US US11/450,292 patent/US20060229238A1/en not_active Abandoned
- 2006-06-12 US US11/450,293 patent/US20060228385A1/en not_active Abandoned
-
2010
- 2010-01-28 JP JP2010016716A patent/JP5757686B2/ja not_active Expired - Lifetime
- 2010-06-07 US US12/795,246 patent/US20100239683A1/en not_active Abandoned
-
2011
- 2011-09-01 US US13/224,105 patent/US8415300B2/en not_active Expired - Lifetime
-
2013
- 2013-06-10 JP JP2013122235A patent/JP2013177449A/ja active Pending
-
2017
- 2017-02-02 CY CY20171100156T patent/CY1118642T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2198888B1 (en) | Sustained release of microcrystalline peptide suspensions | |
AU2002337025A1 (en) | Sustained release of microcrystalline peptide suspensions | |
AU737664B2 (en) | Non-aqueous protic peptide formulations | |
US5916582A (en) | Aqueous formulations of peptides | |
IL167415A (en) | Form of delivery with delayed release of pharmaceutically active peptides and method of production | |
AU2004242540B2 (en) | Aqueous formulations of peptides | |
KR100517091B1 (ko) | 펩티드의수성제제 |